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Simple Summary: Gastric carcinoma (GC) continues to be one of the leading causes of death in
humans and is the most common neoplasm in the stomachs of dogs. In both species, previous
studies have demonstrated that the disease is heterogeneous, with genetic and environmental factors
playing a quintessential role in disease pathogenesis. Compared to humans, the incidence of gastric
carcinoma in dogs is low although, in a small number of breeds, a higher incidence has been reported.
In dogs, the etiology and molecular pathways involved remain largely unknown. This retrospective
study reviews current signalment data, evaluates the inflammatory component and association with
Helicobacter spp. presence in various canine gastric carcinoma histological subtypes, and investigates
potential molecular pathways involved in one of the largest study cohorts to date. The benefit of
such a comparative study is to highlight the parallel histological features and molecular pathways
between dogs and humans.
Abstract: Canine gastric carcinoma (CGC) affects both sexes in relatively equal proportions, with a
mean age of nine years, and the highest frequency in Staffordshire bull terriers. The most common
histological subtype in 149 CGC cases was the undifferentiated carcinoma. CGCs were associated
with increased chronic inflammation parameters and a greater chronic inflammatory score when
Helicobacter spp. were present. Understanding the molecular pathways of gastric carcinoma is
challenging. All markers showed variable expression for each subtype. Expression of the cell
cycle regulator 14-3-3σ was positive in undifferentiated, tubular and papillary carcinomas. This
demonstrates that 14-3-3σ could serve as an immunohistochemical marker in routine diagnosis
and that mucinous, papillary and signet-ring cell (SRC) carcinomas follow a 14-3-3σ independent
pathway. p16, another cell cycle regulator, showed increased expression in mucinous and SRC
carcinomas. Expression of the adhesion molecules E-cadherin and CD44 appear context-dependent,
with switching within tumor emboli potentially playing an important role in tumor cell survival,
during invasion and metastasis. Within neoplastic emboli, acinar structures lacked expression
of all markers, suggesting an independent molecular pathway that requires further investigation.
These findings demonstrate similarities and differences between dogs and humans, albeit further
clinicopathological data and molecular analysis are required.
Keywords: canine; stomach; gastric carcinoma; Helicobacter spp.; p16; 14-3-3σ; E-cadherin and CD44
1. Introduction
Gastric carcinoma is a rare form of cancer in domestic animals, and in dogs accounts for
<1% of all reported neoplasms [1], with adenocarcinoma the most frequent (50–90%) [1]. The
Animals 2021, 11, 1409. https://doi.org/10.3390/ani11051409 https://www.mdpi.com/journal/animals
Animals 2021, 11, 1409 2 of 17
median age of gastric carcinoma development is 10 years, with rough collies, Staffordshire
bull terriers, chow-chows, Belgian shepherds, Norwegian Lundehunds, Cairn terriers and
West Highland white terriers being the breeds most likely to be affected [2].
Compared to gastric carcinoma in humans, the incidence of canine gastric carcinoma
(CGC) is relatively low; however, in recent years the disease has been more frequently
diagnosed [3,4]. Considering the proposed causal effect of diet on gastric neoplasia in hu-
mans [5], this increased frequency in dogs over the last 30 years could be similarly attributed.
Breed predisposition has also contributed [6], with those breeds at increased risk becoming
more popular. In addition, increased longevity and advances in veterinary diagnostic
techniques, such as gastroscopy, may have also contributed to increased diagnosis.
Clinical signs of CGC include vomiting that may progress to hematemesis, melaena,
anemia, lethargy, ptyalism, polydipsia, abdominal distension, and abdominal discomfort.
Prognosis is generally poor, with a median survival time of 35 days, and confirmed
metastasis in about 70–90% of cases at the time of diagnosis or death [7]. Common sites of
metastasis include the gastric lymph nodes, omentum, liver, duodenum, pancreas, spleen,
esophagus, adrenal glands and lungs [2].
Classification of gastric carcinomas in dogs follows the World Health Organization
(WHO) [8] scheme, adapted from humans, which is based on the predominant histological
features and the main patterns of cells within the neoplasm: papillary, tubular, mucinous,
signet-ring cell (SRC) and undifferentiated types [2]. An alternative scheme, again adapted
from human medicine, the Lauren classification, divides tumors into intestinal—cohesive
masses and tubular structures; diffuse—individual or scattered nests of neoplastic cells;
and mixed—incorporating features of both intestinal and diffuse types [9]. Both schemes
have been applied in previous studies [1,3].
The association between chronic inflammation, caused by a variety of factors (bacterial,
viral, and parasitic infections, chemical irritants, and nondigestible particles), and carcino-
genesis is now well established in humans and animals [10]. The risk of carcinogenesis
is higher, the longer the inflammation persists [11]. In humans, it has been shown that
several risk factors, such as Helicobacter pylori infection, diet, and smoking, are involved in
the precancerous cascade of events that lead to gastric adenocarcinomas [12].
The pathogenesis of CGC remains elusive, albeit a high prevalence in certain breeds
(e.g., Staffordshire bull terrier, Norwegian Lundehund and Belgian shepherd dog) suggests
an underlying genetic etiology [6]. A clear role for Helicobacter spp., similar to H. pylori in
humans, has not been reported in domestic species to date [13]. Whether other Helicobacter
spp. are involved with carcinogenesis is unclear. H. pylori has occasionally been recog-
nized in the canine stomach [2,12], however, the predominant species in dogs are H. felis,
H. bizzozeronii and H. heilmannii [14,15]. A clear association between gastric inflammation
and Helicobacter spp. presence has not been made in previous studies, and in addition, an
association with gastric carcinoma has also not been investigated [16].
The role of cell cycle regulators and cell adhesion molecules in cancer is complex and
paradoxical, varying by cell type and stage of tumorigenesis [17]. In this study, we aimed
to examine the involvement of important cell cycle regulators and cell adhesion molecules,
previously studied in human gastric carcinoma, in dogs.
E-cadherin is a calcium-dependent cell–cell adhesion molecule that preserves epithelial
integrity and can act both as a tumor-suppressor and as an oncoprotein [18,19]. A recent
large-scale study separating subtypes according to their growth pattern (polypoid or non-
polypoid, i.e., signet cell, mucinous and undifferentiated carcinoma) showed that there
is a complete loss of E-cadherin in non-polypoid and undifferentiated carcinomas, and
reduced expression in polypoid, with no evidence of malignant alteration or invasion in
canine gastrointestinal tumors [20].
CD44 is a cell surface receptor for hyaluronic acid and binds to collagen, fibronectin
and chondroitin sulfate [21]. Its role in tumorigenesis and metastasis is thought to be
through signaling pathways that regulate cell adhesion, migration, proliferation, differen-
tiation and survival [22,23]. Histopathological studies of human gastric carcinoma have
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associated high CD44 expression with tumor invasion, lymph node metastasis and patient
survival [24–27], although the expression of CD44 in CGC has so far not been investigated.
p16 protein inhibits cyclinD-CDK4/6, and previous studies of human gastric carci-
noma have shown that loss of p16 expression has been associated with increased measures
of malignancy and poor clinical outcome [28]. One previous study showed loss of expres-
sion of p16 in seventeen cases of CGC [29].
14-3-3σ is the focus of much research in human medicine, including gastric carcino-
mas [30,31]. 14-3-3σ protein regulates the G1/S and G2/M cell cycle checkpoints through
sequestration of CDK4, CDK2, and CDK1, and thus prevents mitosis and allows DNA
repair. It may act as a tumor suppressor [32] or it may serve as an oncoprotein. Previously,
in veterinary species, 14-3-3σ has been reported as an oncoprotein in canine mammary and
urinary bladder carcinomas [33,34]. The association and implication of 14-3-3σ with CGC
will be examined later in this study.
The aims of this study were to provide an update on the signalment data and
histopathological classification of a large case series of CGC, and to further investigate
the potential association of chronic inflammation and the presence of Helicobacter spp.
with cancer. Furthermore, using a subset of cases, the expression patterns of four proteins
(E-cadherin, p16, 14-3-3σ and CD44) were studied to determine their potential involvement
in CGC development.
2. Materials and Methods
2.1. Case Selection
The surgical biopsy databases at VPG Histology, United Kingdom, and the SIDAVE-
University of Lleida, Spain were searched for cases of CGC from 2009 to 2019. All cases
included relevant medical records (signalment, clinical history, gross description, micro-
scopic description and original diagnosis), and tissues were received at the Royal Veterinary
College (RVC) as formalin-fixed paraffin-embedded wax blocks. Individually identifiable
owner information was redacted by both supplying institutions. Cases with insufficient
tissue or where the diagnosis was not certain on review were excluded.
A control group of canine gastric biopsy samples was established from cases pro-
vided by VPG and from the RVC pathology archive. Control group samples were defined
based on sample quality, absence of gastric carcinoma, and no previous history of gas-
tric carcinoma. Controls were animals presenting with typical gastrointestinal clinical
signs including vomiting, diarrhea and weight loss; however, no tumor was present on
histopathological examination.
2.2. Histopathological Evaluation
Histological sections, cut at 4 µm and stained with hematoxylin and eosin, were
produced from the provided paraffin blocks and were evaluated microscopically by three
veterinary pathologists (A.H., A.S.-B. and S.L.P.). Each case was confirmed as gastric
carcinoma and further classified according to the WHO standard into five categories:
tubular, papillary, mucinous, SRC, or undifferentiated carcinoma [35,36]. The most frequent
histological pattern served as the main classification criterion for each case.
Mucosal inflammation present within histological sections was assessed using mod-
ified World Small Animal Veterinary Association standards [8,37,38]. For the purposes
of this study, only those parameters consistent with chronic inflammation (intraepithelial
lymphocytes, lamina propria lymphocytes and plasma cells, and gastric lympho-follicular
hyperplasia) were scored as normal—0, mild—1, moderate—2, and marked—3, following
modified WSAVA criteria [37]. A total chronic inflammation score (TCIS, ranging from 0 to
9) was recorded as the sum of the three parameters. Regions of surface ulceration were
avoided when assessing chronic inflammatory parameters.
Sections were stained with Warthin–Starry for Helicobacter spp. identification. Quan-
tification of Helicobacter spp. was performed based on the presence or absence of bacteria
in the mucosa using the following system: 0—no helicobacter found in the sample; 1—low
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numbers of helicobacter found (<15 bacteria per field of highest helicobacter density); and
2—high numbers of helicobacter found (>15 bacteria per field).
2.3. Immunohistochemistry
Immunohistochemical labeling for E-cadherin, CD44, p16 and 14-3-3σ was performed
on 4-µm-thick sections mounted on positively charged slides (SuperFrost Plus; Menzel
Gläser, Braunschweig, Germany). Antigen retrieval, labeling, and counterstaining were
performed on a Bond-Max Autostainer (Leica Biosystems, Newcastle-upon-Tyne, UK)
using the Bond Polymer Refine detection system (Leica Biosystems). Primary antibodies
and retrieval conditions were as follows: p16 (PA0016, 1:100,Novocastra, Newcastle Upon
Tyne, UK); pH 6.0 buffer (ER1, Leica Biosystems) for 20 min, 14-3-3σ (SC-100638, 1:40,
Santa Cruz Biotechnology, Heidelberg, Germany); pH 6.0 buffer (ER1) for 20 min, E-
cadherin (NCH-38, 1:100, Agilent, Stockport, UK); pH 6.0 buffer (ER1) for 20 min, and
CD44 (ab157107, 1:50 Abcam, Cambridge, UK); pH 9.0 buffer (ER2, Leica Biosystems)
for 20 min. Internal positive tissue controls for E-cadherin and CD44 were available on
each section.
2.4. Evaluation of E-Cadherin, CD44, p16 and 14-3-3σ Immunolabeling
Analysis of immunolabeled samples was performed by 3 veterinary pathologists (A.H.,
A.S.-B. and S.L.P.), discrepancies were discussed by use of a multi-headed microscope, and
a consensus was reached. In all cases, areas of ulceration and/or necrosis were avoided for
interpretation.
The distribution and intensity of E-cadherin and CD44 labeling were analyzed for
each case using a similar semiquantitative scoring system. The percentages of tumor
cells, neoplastic acini and intravascular tumor emboli that expressed CD44 and E-cadherin
were assessed. Labeling for CD44 was scored as follows: 0, no labeling; 1, 1–9% positive
tumor cells; 2, 10–49% cells; and 3, 50–99% cells. Labeling for E-cadherin was scored as
follows: 0, no labeling; 1, 1–9% positive tumor cells; 2, 10–49% cells; 3, 50–79% cells; and
4, 80–100% cells. The intensity of E-cadherin and CD44 labeling (0—negative, 1—mild,
2—moderate, and 3—strong) and whether labeling was membranous and/or cytoplasmic
was also recorded [39–41]. A total immunohistochemical score (TIS) [39] for E-cadherin
(ranging from 0 to 12) and TIS CD44 (ranging from 0 to 9) was calculated as the product of
the distribution and intensity scores. Normal gastric surface epithelium served as a positive
internal control for E-cadherin and lymphoid follicles, satellite glial cells and macrophages
for CD44.
For p16, neoplastic cells with cytoplasmic and/or nuclear antigen expression were
interpreted as immunopositive. An immunohistochemical score was assigned based on
the intensity of staining (0—none, 1—weak, 2—moderate, and 3—strong) and percentage
of positive tumor cells (0, 0% cells; 1, <25% cells; 2, 25–50% cells; 3, 51–75% cells; 4, >75%
cells) [42]. The product of the intensity and distribution scores gave a TIS p16 ranging from
0 to 12. As a positive control, normal skin was used where epithelial cells within the basal
layer of the epidermis exhibited weak immunoreactivity.
14-3-3σ labeling was assessed using a previously published semiquantitative scoring
system [43]. The scores for the percentage (1, ≤10% cells; 2, 11–50% cells; and 3, >50% cells)
and staining intensity (0, negative; 1, weak; 2, moderate; and 3, intense) of positive cells
were recorded and a TIS 14-3-3σ (ranging from 0 to 9) was calculated as the product of
these two parameters for each of the studied cases. Normal canine urinary bladder, which
showed cytoplasmic immunolabeling of the urothelium, was used as a positive control.
2.5. Statistical Analysis
Results were analyzed for any significant relationship between the following: signal-
ment (i.e., age, sex and breed); biopsy type (endoscopic vs. full-thickness biopsies); and
histopathological features (tumor classification, chronic inflammation score, helicobacter
identification, quantification, and localization). Statistical comparisons were performed
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using GraphPad Prism version 8.0 for Windows (GraphPad Software, San Diego, CA, USA).
Bar graphs were constructed to depict the mean and standard error of the parameter as-
sessed for each group. To test for the significance of a relationship between two categorical
variables, a Fisher’s test was used to analyze the significance of contingency tables such as
endoscopic vs. full-thickness biopsies for finding helicobacter. An unpaired t-test was used
to compare the mean inflammation scores of different groups. For continuous data, the
Student’s t-test, analysis of variance (ANOVA), or Mann–Whitney U analysis test was used,
depending on whether the data were normally distributed and whether two, or more than
two groups, were compared. The significance level for all statistical tests was set at p < 0.05.
The expression of p16, 14-3-3σ, E-cadherin and CD44 were compared with histological
subtype and features of malignancy.
3. Results
3.1. Case Details and Signalment
One hundred and eighty-two (182) cases of CGC were identified from the archives of
VPG Histology and the University of Lleida and submitted to the Department of Patho-
biology and Population Sciences at the Royal Veterinary College. Following the initial
histopathological review, 149 were suitable for inclusion in the study based on sample
quality, presence of gastric carcinoma, and amount of tumor present in the sample. Cases
included 85 (57.0%) endoscopically obtained (mucosa only) samples, and 64 (44.0%) full-
thickness biopsies collected by surgical excision. Of the 149 dogs, 69 (46.3%) were female,
75 (50.3%) male and 5 (3.4%) of unreported sex. Neuter status was known in 118 cases,
with 88 (74.6%) neutered. Twenty-nine non-tumor control cases were included, 24 (82.8%)
endoscopic and 5 (3.4%) full-thickness biopsies. The control group comprised 15 males
(51.7%), 13 females (44.8%), and one of unreported sex (3.4%). For the carcinoma group the
mean and median ages were 9.1 and 9 years, respectively (range 1–16 years), and for the
control group were 7.5 and 7, respectively.
The Staffordshire bull terrier (22/149, 14.8%) was the breed most frequently affected
by gastric carcinoma. Of the other non-cross breeds, Labrador retrievers (12, 8.1%), golden
retrievers (10, 6.7%), Boxers (9, 6.0%), Border collies (8, 5.4%), rough collies (6, 4.0%), and
Belgian shepherd dogs (6, 4.0%) were also commonly affected (Table S1). A similar range of
breeds was seen in the control population, with Staffordshire bull terriers, Labrador retriev-
ers, Border collies and Belgian shepherd dogs all represented. No statistical correlation
with breed, sex and age was found with regards to each CGC subtype.
3.2. Histopathological Subtypes
Undifferentiated carcinoma was the most frequent carcinoma type overall, comprising
59/149 (39.6%) samples (Table 1). SRC carcinoma made up 47 (31.5%), tubular 32 (21.5%),
and mucinous 10 (6.7%). The papillary type was rare, with only a single case (0.7%)
(Figure 1) There were no significant associations identified between breed or sex and any
of the five classifications of gastric carcinoma.
Table 1. Canine gastric carcinoma subtype by sex.
Gastric Carcinoma Subtype Male Female Not Recorded Total
Undifferentiated 32 26 1 59 (39.6%)
Signet-ring 22 24 1 47 (31.5%)
Tubular 17 12 3 32(21.5%)
Mucinous 4 6 - 10 (6.7%)
Papillary 0 1 - 1 (0.7%)
Total 75 69 5 149
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Figure 1. Gastric carcinoma subtypes and local lymph node metastasis. (a) Papillary adenocarcinoma with characteristic
fibrovascular stalks supporting neoplastic cells that form fingerlike projections (bar = 500 µm). Inset shows increased
mitoses (bar = 20 µm). (b) Tubular adenocarcinoma with neoplastic tubules lined by pleomorphic cells (bar = 20 µm).
(c) Signet-ring cell carcinoma with characteristic signet-ring cells diffusely replacing gastric mucosa (bar = 20 µm). (d)
Mucinous adenocarcinoma with abundant lakes of mucin and occasional small numbers of signet-ring cells (bar = 50 µm). (e)
Undifferentiated adenocarcinoma with neoplastic cells replacing and dissecting through muscularis layers (bar = 200 µm).
Inset showing entotic cell-in-cell (CIC) patterns in an undifferentiated adenocarcinoma (bar = 20 µm). (f) Lymph node
metastasis of a tubular adenocarcinoma with multifocal intravascular neoplastic emboli (bar = 200 µm). Inset shows a
high-power magnification of neoplastic tubule formation within the neoplastic emboli (bar = 20 µm).
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Of the 85 endoscopic samples, 36 (42.4%) were SRC carcinoma, 25 (29.4%) were undif-
ferentiated, 19 (22.3%) tubular, and 5 (5.8%) mucinous. Of the 64 full-thickness samples, 34
(53.1%) were undifferentiated carcinoma, 13 (20.3%) tubular, 11 (17.2%) SRC, and 5 (7.7%)
mucinous. The single papillary adenocarcinoma was recorded amongst the full-thickness
samples (1.5%) (Figure 2). The prevalence of SRC among endoscopic biopsies was signifi-
cantly higher than among full-thickness biopsies (p = 0.0002). Comparisons between other
subtypes in endoscopic and full-thickness biopsies did not show any statistical significance.
Figure 2. WHO classification of 149 canine gastric carcinomas separated by biopsy technique. Full-thickness surgical (FT),
endoscopic (E).
3.3. Inflammation and Presence of Helicobacter spp.
Mean total chronic inflammation score (TCIS) for the control group was 0.5/9 and
for the carcinoma group was 2.8/9. Mean TCIS for the carcinoma group was significantly
higher than that of the control group (p = 0.0001).
Of all subtypes, tubular adenocarcinoma had the highest TCIS, 3.4, followed by
mucinous—3.1, SRC—2.6, and undifferentiated carcinoma—2.5. Papillary adenocarci-
noma had the lowest TCIS of 2.0. All subtypes (except for papillary) had a consistently
significantly greater TCIS when compared with the control group (p = 0.0001) (Figure 3).
Figure 3. Mean total chronic inflammation score (TCIS) by carcinoma histological subtype.
**** p < 0.0001.
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Fifty out of 149 (33.5%) gastric carcinoma samples had observable Helicobacter spp., of
which 19 (38%) had large numbers present. The TCIS of Helicobacter spp. positive samples
was 3.2, versus 2.6 for Helicobacter spp. negative samples. These two means were found to
be significantly different (p = 0.039) (Figure 4).
Figure 4. Mean total chronic inflammation score (TCIS) by helicobacter status for carcinoma and
control groups. H+, helicobacter positive samples, H−, helicobacter negative samples.
Thirteen out of 29 (44.8%) of the control samples had observable Helicobacter spp.,
but only 2 (15.4%) had large numbers present. The TCIS of Helicobacter spp. positive
samples was 0.58, and helicobacter negative samples was 0.50. These two means were not
significantly different.
3.4. Immunohistochemical Assessment of E-Cadherin, CD44, 14-3-3σ and p16
Twenty-two cases of gastric carcinoma, randomly selected from each histopathological
subtype, were available for immunohistochemical assessment as follows: SRC (8, 36.4%),
undifferentiated (7, 31.8%), tubular (5, 22.7%), papillary (1, 4.5%), and mucinous (1, 4.5%).
3.5. E-Cadherin Expression
In normal gastric surface and glandular epithelium, E-cadherin labeling was strong
(3/3 intensity score) and membranous (Figure 5a). Seventeen (of 22) tumors demonstrated
positive immunolabeling for E-cadherin, with both membranous and cytoplasmic (17/22,
77.3%) and nuclear (2/22, 9.1%) labeling, and with an intensity greatest in intravascular
emboli, where present. Five tumors did not show immunopositivity for E-cadherin (2 undif-
ferentiated, 1 SRC, 1 mucinous and 1 tubular carcinoma). Where dysplastic epithelium was
present, E-cadherin expression decreased in intensity and distribution (compared with nor-
mal), and labeling became progressively cytoplasmic (from membranous) (Figure 5b). The
TIS E-cadherin for each tumor subtype was as follows: papillary—6.0; undifferentiated—
4.6; SRC—4.3; tubular—3.2; and mucinous—0 (Table 2). Aberrantly increased expression
and TIS of E-cadherin in intralymphatic/intravascular emboli, compared with both normal
epithelium and immunopositive neoplastic cells, was observed in seven tumors (7/17;
3/7 undifferentiated, 1/8 signet-ring cell and 3/5 tubular carcinoma). E-cadherin was
not expressed by neoplastic emboli composed of well-differentiated acinar structures
(Figure 5c).
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Figure 5. Canine gastric carcinoma immunohistochemistry for E-cadherin, CD44, 14-3-3σ, p16. (a) Expression of E-cadherin
in normal gastric surface and glandular epithelium (bar = 100 µm). (b) Reduced E-cadherin expression (progressively
cytoplasmic from membranous) in neoplastic tubules in a tubular adenocarcinoma (bar = 50 µm). (c) Poorly differentiated
neoplastic cells in emboli showing cytoplasmic and membranous labeling for E-cadherin (bar = 50 µm). (d) Expression of
CD44 in lymphocytes, macrophages and dendritic cells of normal gastric mucosa. (bar = 100 µm) (e) Strong membranous
labeling of CD44 in sheets and chains of poorly differentiated neoplastic cells in an undifferentiated gastric carcinoma
(bar = 200 µm). (f) Loss of membranous and cytoplasmic labeling of CD44 in tubules and strong membranous and cyto-
plasmic labeling in poorly differentiated cells of a neoplastic embolus (bar = 100 µm). (g) Normal epithelium showing no
expression of 14-3-3σ (bar = 100 µm). (h) Strong cytoplasmic with occasional nuclear labeling of 14-3-3σ in nests of poorly
differentiated neoplastic cells in an undifferentiated gastric carcinoma (bar = 20 µm). (i) Loss of cytoplasmic labeling of
14-3-3σ in tubules and cytoplasmic labeling in poorly differentiated cells of a neoplastic embolus (bar = 50 µm). (j) Normal
epithelium showing no expression of p16 (bar = 100 µm). (k) Strong cytoplasmic labeling of p16 in neoplastic epithelium
(bar = 50 µm). (l) Loss of cytoplasmic labeling for p16 in tubules and strong nuclear and cytoplasmic labeling in poorly
differentiated cells of a neoplastic embolus (bar = 50 µm).
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Table 2. Mean total immunohistochemical score by gastric carcinoma subtype. The same score for
neoplastic vascular emboli, where present, is given in parentheses.
Protein
Canine Gastric Carcinoma Subtype
Undifferentiated Signet-Ring Mucinous Tubular Papillary
E-cadherin 4.6 (9) 4.3 (6) 0 3.2 (10) 6
CD44 4.7 (6.3) 3 (6.3) 4 2.4 (3.6) 6
14-3-3σ 3.4 (9) 0 0 2.4 (9) 0
p16 4.3 (9) 6.9 9 6.8 (10.5) 6
3.6. CD44 Expression
In the normal canine stomach, CD44 was expressed on the membrane of lymphocytes,
macrophages, dendritic cells, and satellite glial cells (Figure 5d). Gastric epithelium, stromal
tissue, smooth muscle fibers and matrix fibroblasts were negative. Positive immunolabeling
(neo-expression) occurred in all gastric carcinoma cases. CD44 expression was cytoplasmic
and membranous (5/22, 22.7%) or only membranous (9/22, 40.9%), with an intensity great-
est in mucinous tumors (mean intensity score 2.5). Enhanced membranous expression was
observed in those neoplastic epithelial cells that showed the greatest features of malignancy
(pleomorphism and invasion), with a higher mean score in papillary, undifferentiated and
tubular carcinomas (6, 4.7 and 4, respectively) (Figure 5e). Intravascular neoplastic emboli,
present in 4/7 undifferentiated, 4/5 tubular and 3/7 SRC carcinomas, showed increased
TIS compared to immunopositive neoplastic cells. Neoplastic cells in emboli exhibited
membranous, or both cytoplasmic and membranous expression, in poorly differentiated
neoplastic cells. Interestingly, there were neoplastic emboli that had solid nests and well-
differentiated acinar arrangements, and, in these emboli, only the solid nests were strongly
positive, while the well-differentiated embolic acini were negative (Figure 5f).
3.7. 14-3-3σ Expression
In a histologically normal canine stomach, 14-3-3σ was not expressed in any cell types,
including epithelium, stromal tissue or lymphocytes (Figure 5g). Positive immunolabeling
(neo-expression) occurred in 10 of 22 (45.4%) gastric carcinomas, 7/7 undifferentiated,
and 3/5 tubular. TIS 14-3-3σ for undifferentiated and tubular carcinomas was 3.4 and
2.4, respectively. SRC, papillary and mucinous carcinomas were all negative for 14-3-3σ.
Cytoplasmic and/or nuclear neo-expression of 14-3-3σ was present, with an intensity
greatest in undifferentiated tumors (intensity mean 2.1, and total score 3.4). One case of
undifferentiated carcinoma showed both nuclear and cytoplasmic labeling in neoplastic
cells (Figure 5h). Where neoplastic emboli were present, TIS was higher compared to
immunopositive neoplastic cells, and 14-3-3σ labeling intensity was increased in poorly
differentiated and pleomorphic cells. However, when neoplastic cells formed intravascular
acinar structures, 14-3-3σ was not expressed (Figure 5i).
3.8. p16 Expression
In a histologically normal canine stomach, p16 was not expressed (Figure 5j), but
positive cytoplasmic and/or nuclear labeling was noted in regions of dysplastic epithelium
(Figure 5k). p16 expression occurred in 19/22 (86.4%) carcinomas; 6/7 undifferentiated,
5/5 tubular, 1/1 papillary, 6/8 SRC, and 1/1 mucinous. Positive immunolabeling of
pleomorphic cells and dysplastic tubules was found in all tumors, with high-grade ex-
pression in mucinous tumors (signet-ring cells in SRC and mucinous carcinomas were
strongly immunopositive for p16). p16 exhibited cytoplasmic (11/22, 50%) and both nu-
clear/cytoplasmic (8/22, 36.36%) expression, with intensity greatest in mucinous tumors
(intensity mean 3 and total score 9).
Where neoplastic emboli were present, TIS was higher compared to immunopositive
neoplastic cells. Within intravascular and intralymphatic emboli, p16 intensity and cyto-
plasmic and/or nuclear expression was increased in poorly differentiated and pleomorphic
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cells. However, when neoplastic cells formed intravascular acinar structures, p16 was not
expressed (Figure 5l). Similar findings were noted in the lymph node metastasis of one
sample. The mean TIS p16 for undifferentiated, tubular, papillary, SRC and mucinous
carcinomas was 4.3, 6.8, 6, 6.9 and 9, respectively.
4. Discussion
In this canine gastric carcinoma (CGC) study, using the WHO scheme, we have
demonstrated that the most frequent subtype is the undifferentiated carcinoma, and the
most common breed affected is the Staffordshire bull terrier. There is no sex predisposition,
and the mean age is nine years. Helicobacter spp. presence was associated with increased
chronic inflammation parameters and a greater chronic inflammatory score. We found
that all markers showed variable expression for each subtype. CD44 and 14-3-3σ have not
been previously investigated in CGC. 14-3-3σ was positive in undifferentiated, tubular and
papillary carcinomas, and p16 expression was increased in mucinous and SRC carcinomas.
E-cadherin and CD44 were variably expressed in all subtypes and were associated with
criteria of malignancy. Within neoplastic emboli, acinar structures lacked expression of all
markers, suggesting an independent molecular pathway that requires further investigation.
Of the 149 dogs included in this study from the UK and Spain, the mean and median
age of 9.1 and 9 years, respectively, at the time of CGC diagnosis is in broad agreement
with previously reported studies [3,6,7]. In this study, CGC affected male and female dogs
roughly equally, with a slight preponderance towards males, as is consistent with previous
reports [3]. The most commonly affected breed was the Staffordshire bull terrier, likely
reflecting both the general population in the United Kingdom (only 2/22 Staffordshire
bull terriers were from Spain) and previous reports of breed predisposition [7]. Breed
predisposition to CGC is also reported in less common breeds, including Belgian shepherd
dogs and rough collies, which also appeared with an increased frequency in this study [3,6].
Using the WHO classification for domestic animals, cases were divided into five
categories based on the predominant histological features and the principal cell type of
the tumor. All histological subtypes of carcinoma (SRC, tubular, mucinous, papillary
and undifferentiated) were recorded, although squamous cell carcinoma, another CGC
subtype, was not present in this study [44]. Undifferentiated carcinoma was the most
frequent subtype, followed by SRC, contrary to the previous studies reporting an increased
frequency for the tubular subtype, similar to humans [45,46]. This could likely reflect a
geographic variation in gastric adenocarcinoma incidence.
Signet-ring cell carcinomas were the most frequently diagnosed type by endoscopy,
whereas undifferentiated carcinomas were the most frequently diagnosed in full-thickness
samples. The most likely reason behind this difference is that, histologically, the diagnosis
of SRC subtype is based upon identification of the characteristic isolated or small groups
of malignant cells containing intracytoplasmic mucin with an eccentric nucleus (signet-
ring cells) within the mucosa, and hence, diagnosis from an endoscopically retrieved
(mucosa only) sample is possible. The diagnosis of other histopathological subtypes
typically requires the evaluation of invasion beyond the mucosa, and thus, given the
relatively high number of full-thickness biopsies in this study, this may have influenced the
predominant subtype. Additionally, signet-ring cells were also present in other subtypes,
i.e., mucinous and undifferentiated carcinoma; however, the predominant histological
features and pattern did not favor a diagnosis of SRC carcinoma. This suggests that
endoscopic samples alone can lead to diagnostic pitfalls between different subtypes [47–50].
In humans, novel techniques such as endoscopic surgical dissection are recommended in
subtypes like SRC that spread subepithelially in the margins [51]. In combination with
future novel imaging techniques, these findings should be taken into consideration to
determine the appropriate sampling and therapeutic approach [52].
Cancer-related inflammation is one of the hallmarks of neoplasia, and once cancer
develops, there is evidence of a substantial shift in the microenvironment affecting the
immune response [53,54]. A simplified histopathologic scoring system was adapted to
Animals 2021, 11, 1409 12 of 17
reduce variability in the diagnostic interpretation [37]. This scoring system captured and
quantified chronic inflammatory changes in the gastric mucosa [55]. The TCIS for the
carcinoma group, and individually for each CGC subtype (independent of helicobacter
presence), was significantly greater when compared to the control group’s TCIS. Thus, there
is a clear correlation between chronic inflammation and carcinoma for most CGC subtypes.
Given the link between the presence of helicobacter, inflammation and neoplasia in
humans we aimed to quantitatively assess helicobacter presence in CGCs. In previous
studies Helicobacter spp. have been reported in both neoplastic and non-neoplastic canine
stomachs [56,57]. In this study, the TCIS of the carcinoma group with a concomitant
presence of helicobacter was significantly greater compared to the helicobacter-negative
carcinoma group. Furthermore, larger numbers of helicobacter were found in carcinoma
cases than in control cases. Although the helicobacter presence does not prove a definite role
in CGC pathogenesis, there is a clear association between increased chronic inflammation
and higher numbers of helicobacter in the tumor cases versus controls. Whether the
presence of Helicobacter spp. is associated with tumor development is not exactly clear, and
thus further studies, perhaps to examine particular species of helicobacter in association
with CGC, would be needed.
To understand the molecular pathways and investigate the cellular origin of CGC, the
expression of cellular adhesion molecules (E-cadherin and CD44) and cell cycle regulators
(p16 and 14-3-3σ) were investigated in a representative proportion of cases. CD44 and
14-3-3σ have not previously been studied in CGC.
E-cadherin controls cell motility and suppresses tumor growth and metastasis [58].
Immunohistochemical examination of E-cadherin in all tumor subtypes identified abnor-
malities of expression and localization. Dysplastic surface and glandular epithelia in
immunopositive cases revealed a reduction in E-cadherin expression. Pleomorphic cells in
the undifferentiated subtype showed E-cadherin expression, albeit in decreased intensity
compared to the normal epithelium. Subcellular localization of E-cadherin was observed
in the majority of neoplastic cells. Intracytoplasmic sequestration and the accumulation
of E-cadherin have been previously associated with abnormalities in the intracytoplasmic
transport and reuptake mechanisms of the molecule [59,60]. Aberrant nuclear expression
of E-cadherin in humans has been previously described in several tumor types including
gastric and colorectal carcinomas [19,61]. Similarly, increased intensity intracytoplasmic
and nuclear expression was noted in the neoplastic emboli composed of pleomorphic
neoplastic cells forming solid nests. Surprisingly, intravascular acinar structures did not
express E-cadherin. Furthermore, tubular adenocarcinoma, which is composed of acini
and tubules, had the lowest TIS compared to other subtypes. This could represent an
inverse association between the reduction or loss of E-cadherin with an increasing degree
of differentiation, where well-differentiated structures switch off and pleomorphic cells
switch on or increase the expression of E-cadherin. Previous studies in human gastric
adenocarcinoma showed that abnormalities of E-cadherin localization (internalization)
in neoplastic cells lead to decreased adhesion, thus favoring invasion [59,60]. Neoplastic
cells lacked E-cadherin expression in discohesive subtypes like mucinous adenocarcinoma,
which is in accordance with a recent study [20].
In the context of these findings, we postulate that the reduction or loss of E-cadherin
expression on the cell membrane could potentially facilitate invasion, and that the re-
expression of E-cadherin, including on the cell membrane, in neoplastic emboli could lead
to the development of solid cohesive intravascular structures, enhancing their survival.
These findings reinforce the notion that E-cadherin in CGC is a context-dependent adhesion
molecule that can either be up- or down-regulated or re-expressed, depending on the stage
of tumor progression [62]. Further studies analyzing ligands of E-cadherin and possible
mutations are required to clarify its precise role in CGC.
CD44 serves as a signaling platform, with transmembrane and cytoplasmic domains
as a co-receptor for various types of cell surface receptors that modulate cell adhesion,
migration, proliferation, differentiation and survival [63–66]. In humans, its role in the
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adaptive plasticity and survival of cancer cells in processes like epithelial to mesenchymal
transition, invasion and metastasis has been widely studied [67,68]. In CGC, CD44 was
variably expressed in all tumor subtypes. Similar to E-cadherin, the expression of CD44
was enhanced in pleomorphic neoplastic cells and was absent in well-differentiated acinar
structures within neoplastic emboli. In the context of these findings, we postulate that CD44
expression could potentially facilitate invasion and expression in neoplastic emboli and,
alongside E-cadherin, could lead to the development of cohesive intravascular structures,
enhancing their survival. In previous studies in humans, CD44 positive cells in gastric cell
lines were associated with increased chemoresistance and invasiveness [66]. Additionally,
CD44 positive gastric tumors were associated with larger tumor size, a lower grade of
differentiation, tumor relapse, lymph node invasion, distant metastasis and reduced sur-
vival [63–66]. It seems that CD44 may represent an important biomarker and a promising
therapeutic target in canine gastric carcinomas.
14-3-3σ is a cell cycle regulator that may serve as either a tumor suppressor or an
oncogene involved in tissue invasion and metastasis. Histological features of malignancy
have been previously associated with the overexpression and/or neo-expression of the
protein [69,70]. The role of this protein as a tissue differentiation marker and as an onco-
protein in veterinary medicine has been previously studied in canine mammary, urinary
bladder, renal cell and equine penile squamous cell carcinomas [33,34,71,72]. In the current
study, immunohistochemical analysis revealed the absence of 14-3-3σ immunolabeling in a
normal stomach and in SRC and mucinous carcinomas. The latter finding was consistent
for all cases of the two subtypes and likely demonstrates a 14-3-3σ independent molecular
pathway in carcinogenesis. In contrast, tubular and undifferentiated subtypes showed
strong intracytoplasmic neoexpression, and occasionally nuclear expression of 14-3-3σ. The
single papillary carcinoma had weak intracytoplasmic neoexpression. Undifferentiated
carcinomas demonstrated strong intracytoplasmic, and occasionally nuclear, expression in
the most pleomorphic neoplastic cells. Similarly, in those tumors with neoplastic emboli
formed by pleomorphic cells forming solid nests, there was strong intracytoplasmic and
occasionally nuclear expression of 14-3-3σ. However, acinar structures within the intravas-
cular emboli lacked expression of 14-3-3σ. Aberrant nuclear expression of 14-3-3σ, in a
subset of cases of renal cell carcinomas, was associated with a malignant phenotype and
shorter survival rate [43]. Thus, we hypothesize, in view of these findings, that expres-
sion of 14-3-3σ is associated with features of malignancy, and that neoexpression of the
molecule is essential in the stage of intravascular invasion. Expression of the protein in
the extracellular milieu, as previously demonstrated for other canine carcinomas, was not
observed in this study [72].
The protein p16 acts as a tumor suppressor and a cell cycle regulator, by slowing
progression from the G1 to S phase through the inhibition of cyclinD-CDK4/6. Its role
and possible relationship to tumor progression and prognosis have been studied in a
variety of human tumors [73–75]. In human gastric carcinomas, loss of p16 expression
has been associated with malignant characteristics and poor prognosis [28,76,77]. In the
CGCs studied here, the expression of p16 seemed to be an event common to all subtypes,
and thus appears fundamental for neoplasia development, with expression most strong
in mucinous and SRC carcinomas. Half of the tumors showed cytoplasmic, and 36.7%
both nuclear and cytoplasmic, immunolabeling. Within neoplastic emboli, expression was
cytoplasmic and only in one tubular carcinoma case was both cytoplasmic and nuclear.
Similar to the other markers, when acinar structures were present within the emboli, p16
expression was absent. These results contradict a previous canine study, where lack of p16
expression in tubular, SRC and undifferenced subtypes was significantly associated with
histological criteria of malignancy in 14 cases [29]. In humans, the overexpression of p16 is
associated with mutations in genes encoding retinoblastoma protein (Rb) and p53, and is
considered to be a mechanism to arrest the uncontrolled proliferation caused by failure
of the Rb pathway [78]. Furthermore, the significance of the p16 expression within the
cell is not clear, and few studies have associated cytoplasmic expression with malignant
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features [79]. Currently, similar to humans, the significance of p16 expression patterns in
CGC remains unclear [78].
5. Conclusions
In conclusion, CGC affects female and male dogs in relatively equal proportions, with
a mean age of nine years, and the highest frequency in Staffordshire bull terriers. The
most common CGC histological subtype was the undifferentiated carcinoma. CGCs were
associated with increased chronic inflammation parameters and with a greater chronic
inflammatory score when Helicobacter spp. were present. Understanding the altered molec-
ular pathways associated with gastric carcinoma development including its histological
subtype remains a challenge. The significance of the findings from the cell cycle regulators
and cell adhesion molecules in the subtypes examined, should be combined with clinico-
pathological data and additional molecular analysis to further understand the molecular
mechanisms and similarities between dogs and humans.
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